Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types

Circulation

Volumn 120, Issue 13, 2009, Pages 1203-1212

  Rapezzi, Claudio ^a   Merlini, Giampaolo ^b   Quarta, Candida C ^a   Riva, Letizia ^a   Longhi, Simone ^a   Leone, Ornella ^b   Salvi, Fabrizio ^c   Ciliberti, Paolo ^a   Pastorelli, Francesca ^c   Biagini, Elena ^a   Coccolo, Fabio ^a   Cooke, Robin M T ^a   Bacchi Reggiani, Letizia ^a   Sangiorgi, Diego ^a   Ferlini, Alessandra ^d   Cavo, Michele ^a   Zamagni, Elena ^a   Fonte, Maria Luisa ^b   Palladini, Giovanni ^b   Salinaro, Francesco ^b   Musca, Francesco ^b   Obici, Laura ^a,b   Branzi, Angelo ^a   Perlini, Stefano ^b   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c BELLARIA HOSPITAL   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

Amyloid; Cardiomyopathy; Echocardiography; Electrocardiography; Myocardium; Myocytes, cardiac

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PREALBUMIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE COURSE; ELECTROCARDIOGRAM; FEMALE; GENE MUTATION; HEART AMYLOIDOSIS; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QRS COMPLEX; SURVIVAL;

ADULT; AGED; AMYLOIDOSIS; BLOOD PRESSURE; CARDIOMYOPATHIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIUM; MYOCYTES, CARDIAC; POINT MUTATION; PREALBUMIN; PULMONARY WEDGE PRESSURE; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 70349655715     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.843334     Document Type: Article

References (33)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583-596.
2. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD. Amyloid protein fibril nomenclature. Amyloid. 2002;9:197-200.
3. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898-909.
4. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc. 1999;74:490-494.
5. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79:319-328.
6. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid. 2002;9:108-114.
7. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;6:346:1786-1791.
8. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047-2060.
9. Ferlini A, Fini S, Salvi F, Patrosso MC, Vezzoni P, Forabosco A. Molecular strategies in genetic diagnosis of transthyretin-related hereditary amyloidosis. FASEB J. 1992;6:2864-2866.
10. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, Thibodeau SN. The premortem recognition of systemic senile amy-loidosis with cardiac involvement. Am J Med. 1996;101:395-400.
11. Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly. 2006;136:715-720.
12. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165:1425-1429.
13. Surawicz B, Knilans TK. Chou?s Electrocardiography in Clinical Practice. 5th ed. Philadelphia, Pa: Saunders; 2001.
14. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO; American College of Cardiology; American Heart Association; American Society of Echocar-diography. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation. 2003;108:1146-1162
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
16. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol. 1998;32:865-875.
17. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982; 49:9-13.
18. McCarthy RE, Kasper EK. A review of the amyloidoses that infiltrate the heart. Clin Cardiol. 1998;21:547-552.
19. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart. 1997;78:74-82.
20. Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, Goldschmidt H, Katus HA, Dengler TJ. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2007;9:617-624.
21. Johansson B, Westermark P. Senile systemic amyloidosis: a clinico-pathological study of twelve patients with massive amyloid infiltration. Int J Cardiol. 1991;32:83-92.
22. Misu K, Hattori N, Nagamatsu M, Ikeda S, Ando Y, Nakazato M, Takei Y, Hanyu N, Usui Y, Tanaka F, Harada T, Inukai A, Hashizume Y, Sobue G. Late-onset familial amyloid polyneuropathy type I (transthyretin met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan: clinicopathological and genetic features. Brain. 1999;122:1951-1962.
23. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amy-loidotic polyneuropathy. Arch Neurol. 2005;62:1057-1062.
24. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, Liao R. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94:1008-1010.
25. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d?Eril GM, Moratti R, Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440-2445.
26. Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci U S A. 1995;92:1989-1993.
27. Suhr OB, Anan I, Backman C, Karlsson A, Lindqvist P, Mörner S, Waldenström A. Do troponin and B-natriuretic peptide detect cardiomy-opathy in transthyretin amyloidosis? J Intern Med. 2008;263:294-301.
28. Palladini G, Saraiva MJ, Coelho T, Reis H, Obici L, Vezzoli M, Vadacca G, Merlini G, Perlini S. Differential effects on amyloid-induced myo-cardial dysfunction and N-terminal-pro brain natriuretic peptide release of different amyloidogenic proteins. Eur Heart J. 2004;25(suppl):36. Abstract.
29. Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, Hare JM, Baughman KL, Kasper EK. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004;43: 410-415.
30. Rapezzi C, Perugini E, Salvi F, Grigioni F, Riva L, Cooke RM, Ferlini A, Rimessi P, Bacchi-Reggiani L, Ciliberti P, Pastorelli F, Leone O, Bartolomei I, Pinna AD, Arpesella G, Branzi A. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid. 2006;13: 143-153.
31. Bittencourt PL, Couto CA, Clemente C, Farias AQ, Palacios SA, Mies S, Goldberg AC. Phenotypic expression of familial amyloid polyneuropathy in Brazil. Eur J Neurol. 2005;12:289-293.
32. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology. 2002;58:1001-1007. (Pubitemid 34298536)
33. Planté-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, Said G, Bonay ti-Pellié G. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet. 2003;40:e120.